Found 699 none trials
A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Patients with moderate to severe Crohn's disease, who have failed prior treatment with the standard anti-TNF therapy will receive the study medication - MDGN-002 - which may help treat the Crohn's disease and relieve its symptoms.
This is a single-arm phase II study of twenty-one subjects with mucinous adenocarcinoma of the colon, rectum, or appendix with prior systemic therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Treatment will consist of nivolumab every 4 weeks and ipilimumab every 8 weeks until disease progression, unacceptable toxicity, or 2 years …
You are invited to participate in a research study that will look at the impact of primary sclerosing cholangitis on the gut.
The main purpose of this study is to examine the efficacy of adding itacitinib (also known as INCB039110) to pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.
The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for MPM
AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody to the inhibitory receptor Siglec-8, present on mast cells, eosinophils, and basophils. Binding of AK002 to Siglec-8 induces a signal that inhibits mast cell activation and can lead to apoptosis in eosinophils. In the presence of effector cells (such as …
The outlined research study is not of therapeutic intent, involving only the collection of blood, cerebrospinal fluid, and tissue samples to evaluate pharmacokinetics and resistance.
This study will evaluate the efficacy and safety of fitusiran compared to on-demand treatment with factor concentrates, as determined by the frequency of bleeding episodes in enrolled patients.
This is a Phase 2 open-label, single-arm design with dose escalation by subject cohort and with the potential for individual titration (dose increase or decrease) within each cohort. Five PTG-300 dose levels/regimens are planned to be tested for each subpopulation of beta-thalassemia (NTD and TD) on separate arms: Cohort 1: …
The purpose of this study is to determine the effects of sirolimus in patients (males or females aged 18-80) with idiopathic multicentric Castleman Disease (iMCD) who are either unable to tolerate siltuximab or tocilizumab, or have failed, relapsed, or are refractory to this treatment. Subjects will take sirolimus daily for …
